United States Drug Manufacturers - General news

20:46 15 Jul 2026

Fierce Pharma Regulatory and legal Main company 🇺🇸 United States

Sanofi opens new chapters in Pfizer, Moderna mRNA patent litigation sagas

Sanofi has initiated new patent infringement lawsuits against Pfizer and Moderna, targeting the lipid nanoparticle (LNP) technology used in their COVID-19 vaccines and Moderna's RSV vaccine. Sanofi claims the LNP tech, developed by its acquired Translate Bio, infringes on its patents related to mRNA …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

20:15 15 Jul 2026

Morningstar Earnings Main company 🇺🇸 United States

Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility

Johnson & Johnson reported a 6.6% revenue growth in the second quarter, driven by strong performances in Innovative Medicine and MedTech, leading management to increase 2026 guidance. While shares dropped 2% intraday, Morningstar is maintaining its $190 fair value estimate, noting J&J's robust oncology …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

19:43 15 Jul 2026

Fierce Pharma Earnings Main company 🇺🇸 United States

Novo gains head start on Lilly with European Commission approval of Wegovy pill

Novo Nordisk has secured a head start over Eli Lilly in Europe with the European Commission's marketing authorization for the Wegovy pill for obesity and overweight adults. This approval makes it the first GLP-1 receptor available in tablet form in Europe. The European Commission …

LLY main company NVO main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

18:56 15 Jul 2026

BioSpace Earnings Main company 🇺🇸 United States

Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain

Johnson & Johnson is restructuring its pharmaceutical supply chain, announcing up to $750 million in costs to streamline operations, including offloading certain sites. This move follows a $55 billion commitment to bolster U.S. manufacturing capabilities for medicines in the U.S. The company reported strong …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

18:37 15 Jul 2026

Zacks Earnings Main company 🇺🇸 United States

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers Squibb (BMY) has seen a 1.8% return over the past month, slightly outperforming the S&P 500 composite. The company's earnings estimates have been revised upwards, with a Zacks Rank #3 (Hold), and it reported strong revenue and EPS beats in the last …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

18:25 15 Jul 2026

Benzinga Earnings Main company 🇺🇸 United States

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer

Merck announced that its blockbuster drug Keytruda outperformed chemotherapy in a Phase 3 trial for advanced or recurrent endometrial cancer, meeting its primary endpoint of progression-free survival. Keytruda is the first and only PD-1 inhibitor to show significant improvement as monotherapy in this patient …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

18:10 15 Jul 2026

Reuters Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk wins EU approval for Wegovy weight-loss pill

Novo Nordisk has received EU approval for its once-daily Wegovy pill for weight management in adults with obesity or who are overweight, marking it as the first oral GLP-1 weight-loss treatment cleared for use across the EU. The approval, based on clinical trial data …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

18:08 15 Jul 2026

BioSpace Earnings Main company 🇺🇸 United States

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.34 per share for the third quarter of 2026. This dividend will be payable on September 8, 2026, to shareholders recorded by August 25, 2026. The ex-dividend date is also set for August …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

17:10 15 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Bristol Myers Squibb (BMY), a biopharmaceutical company within the Zacks Medical - Biomedical and Genetics industry, has a strong track record of surpassing earnings estimates in its last two reports, with an average surprise of 9.64%. With recent estimates moving higher and a positive …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

17:04 15 Jul 2026

Reuters Regulatory and legal Main company 🇺🇸 United States

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's patent rights, specifically those covering …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

16:45 15 Jul 2026

Simply Wall Street Regulatory and legal Main company 🇺🇸 United States

Amgen’s Tablet Recalls Test Its Quality Controls and Manufacturing Ambitions (AMGN)

Amgen recently initiated nationwide US recalls of certain Sensipar and Corlanor tablet lots due to FDA-identified manufacturing deviations and foreign substances. These Class II recalls raise concerns about Amgen's operational oversight and regulatory risk management, especially as the company aims to scale complex biologics …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

16:38 15 Jul 2026

Quartz Earnings Main company 🇺🇸 United States

Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength

Johnson & Johnson reported strong Q2 2026 earnings, surpassing expectations with $25.31 billion in sales, primarily driven by its Innovative Medicine unit. The company also raised its full-year revenue outlook to $101.1 billion, a historic milestone. Growth in cancer and immunology drugs offset declines …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

16:34 15 Jul 2026

Proactive financial news Earnings Main company 🇺🇸 United States

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies

Jefferies notes that strong Q2 sales of Johnson & Johnson's Spravato, a depression treatment, indicate a promising long-term commercial opportunity for psychedelic drugs in treating mental health disorders. The drug's annual revenue run rate of over $2.3 billion and its potential to reach $3 …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

16:13 15 Jul 2026

Market source Deals and strategy Main company 🇺🇸 United States

J&J raises FY26 outlook following positive Q2

Johnson & Johnson (J&J) reported strong Q2 revenues of $25.3 billion, a 6.6% year-over-year increase, primarily driven by its Innovative Medicine business and J&J MedTech. Following these results, the company raised its 2026 earnings outlook to $11.60-$11.75 per share. Despite the positive outlook, J&J's …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

16:07 15 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

Biogen's shares fell by 8.2% after presenting data from its phase II CELIA study for the experimental Alzheimer’s drug, diranersen, which failed to meet its primary endpoint. Although the drug showed meaningful reductions in cognitive decline, it did not demonstrate the expected dose-response relationship, …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

15:58 15 Jul 2026

Bloomberg Law News Market update Main company 🇺🇸 United States

Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties

Sanofi has filed federal lawsuits against Moderna Inc. and Pfizer Inc., seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that these vaccines infringe upon as many as 10 of its mRNA delivery patents. The lawsuits were filed in the US District …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

15:24 15 Jul 2026

Market source Regulatory and legal Main company 🇺🇸 United States

Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC

Pfizer and Astellas Pharma announced FDA approval of PADCEV plus Keytruda as a neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), marking the first platinum-free regimen approved for MIBC regardless of cisplatin eligibility. This approval expands on a previous FDA …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

15:15 15 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

Merck & Co Inc Stock (MRK) Moved Up by 3.05% on Jul 15: Key Drivers Unveiled

Merck & Co Inc (MRK) shares rose by 3.05% on July 15, driven by positive oncology clinical data and robust pipeline developments in its cardiovascular and immunology segments. Analysts have revised forecasts upward due to improved operational margins and strategic capital allocation, positioning healthcare …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

14:41 15 Jul 2026

Stock Titan Deals and strategy Main company 🇺🇸 United States

GSK (NYSE: GSK) closes $10.6B Nuvalent deal to expand lung cancer pipeline

GSK has completed its $10.6 billion acquisition of Nuvalent, a clinical-stage biopharmaceutical company, significantly expanding its oncology pipeline. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655), which have FDA Breakthrough Therapy and Orphan Drug Designations and are expected to …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

14:37 15 Jul 2026

Investing.com Market update Main company 🇺🇸 United States

Biogen names Michael Parini as chief legal officer

Biogen Inc. has appointed Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of experience in the biopharmaceutical industry, having previously served as CEO of Spur Therapeutics and held leadership roles at Vertex Pharmaceuticals and …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

14:10 15 Jul 2026

24/7 Wall St. Earnings Main company 🇺🇸 United States

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced "death crosses" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% dividend yield, …

GILD main company PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

13:53 15 Jul 2026

Seeking Alpha Market update Main company 🇺🇸 United States

Novo wins EU nod for Wegovy pill and higher-dose Wegovy in single-dose pen

Novo Nordisk has received marketing authorization from the European Commission for its Wegovy pill and a higher-dose version of the Wegovy injectable in a single-dose pen. This approval means the once-daily oral option will be available across 27 EU countries.

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

13:49 15 Jul 2026

Market source Earnings Main company 🇺🇸 United States

NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart

Novo Nordisk's oral Wegovy has received EU approval for weight management, causing NVO stock to jump 2.5%. This marks the fifth regulatory approval for the oral pill worldwide, and the company plans to launch it in more countries by late 2026. Retail investors have …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

13:13 15 Jul 2026

Quiver Quantitative Earnings Main company 🇺🇸 United States

VivoSim Labs Announces $5 Million Lilly Milestone Payment and FY2027 Revenue Growth Guidance

VivoSim Labs announced it received a $5 million milestone payment from Eli Lilly, tied to the progression of an inflammatory bowel disease drug into Phase 2 studies. The company also projects over 500% revenue growth for Fiscal Year 2027, driven by increasing demand for …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

13:07 15 Jul 2026

NeurologyLive Earnings Provider-linked mention 🇺🇸 United States

Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3

Biogen's anti-tau agent, diranersen, demonstrated significant slowing of cognitive decline across multiple endpoints in the Phase 2 CELIA trial for early Alzheimer's disease. The 60 mg dose showed the most consistent clinical benefit, including a 26% slowing on CDR-SB and reductions in CSF total …

BIIB mentioned

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

12:11 15 Jul 2026

EQS News Deals and strategy Provider-linked mention 🇺🇸 United States

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada | Corporate

Septa Pharmaceuticals Inc. has announced the acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada, as of June 29, 2026. This acquisition strengthens Septa's specialty oncology pharmaceutical portfolio with an essential chemotherapy medication used primarily for brain tumors and Hodgkin's lymphoma. Septa is committed …

BMY mentioned

Sharemaestro market context Trend signal active 52 weeks +38.1%

12:03 15 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Once-weekly HIV combinations among Merck’s AIDS 2026 late-breakers

Merck announced it will present new data on daily, weekly, and monthly HIV treatment and prevention options from its pipeline at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. Key presentations will feature late-stage clinical trial results for investigational once-weekly …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

11:54 15 Jul 2026

MassDevice Earnings Main company 🇺🇸 United States

Johnson & Johnson MedTech sales grow 4.5% in Street-beating Q2, ups guidance

Johnson & Johnson (J&J) reported strong Q2 2026 results, surpassing Wall Street expectations with 4.5% growth in MedTech sales and overall sales of $25.3 billion. The company also raised its full-year revenue and adjusted EPS guidance, now expecting annual revenue to exceed $100 billion …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

11:41 15 Jul 2026

Johnson & Johnson Earnings Main company 🇺🇸 United States

Johnson and Johnson Earnings Report | 2026 Q2 Infographic

Johnson & Johnson released its second-quarter 2026 earnings report, highlighting strong performance in its Innovative Medicine and MedTech businesses. The company reported a 6.6% increase in sales to $25.3 billion, with operational growth of 5.6%, and an adjusted EPS of $2.90. Joe Wolk, EVP …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

11:36 15 Jul 2026

MarketBeat Earnings Main company 🇺🇸 United States

Livforsakringsbolaget Skandia Omsesidigt Purchases 10,752 Shares of Amgen Inc. $AMGN

Livforsakringsbolaget Skandia Omsesidigt increased its stake in Amgen Inc. by 18.7% in the first quarter, now owning 68,130 shares valued at $23.95 million. This makes Amgen its 22nd biggest holding, constituting 1.0% of its portfolio. Other institutional investors also adjusted their positions in Amgen, …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

11:34 15 Jul 2026

Barron's Earnings Main company 🇺🇸 United States

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson exceeded second-quarter earnings and revenue expectations, prompting the company to raise its full-year guidance. This growth was primarily driven by the strong performance of its oncology portfolio, despite a decline in sales for its drug, Stelara. Despite the positive financial results, …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

11:32 15 Jul 2026

WSJ Earnings Main company 🇺🇸 United States

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson has raised its full-year guidance for sales and adjusted earnings per share after reporting higher sales in the latest quarter. The company now expects full-year sales of $100.8 billion to $101.4 billion and adjusted earnings per share between $11.60 to $11.75, …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

11:27 15 Jul 2026

Reuters Earnings Provider-linked mention 🇺🇸 United States

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson surpassed Wall Street expectations for its second-quarter sales and profit, primarily driven by strong performance in its pharmaceutical unit, particularly from Darzalex and Tremfya. The company also raised its full-year sales and profit outlook, despite a slight dip in its medical …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +48.8%

11:13 15 Jul 2026

Investing.com Canada Market update Main company 🇺🇸 United States

Form S-1 Biogen Inc For: 15 July By Investing.com

This article from Investing.com announces the filing of Form S-1 by Biogen Inc. on July 15. The content primarily consists of navigation links, market data, and unrelated news headlines, providing minimal specific details about the Biogen filing itself.

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

10:37 15 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s Data - Has The Bull Case Changed?

Biogen's stock is down 6.7% following the launch of at-home LEQEMBI IQLIK for early Alzheimer's and new positive Phase 2 data for diranersen. The at-home option for LEQEMBI aims to improve access and uptake, which is crucial for Biogen's investment narrative amidst revenue pressure …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

10:15 15 Jul 2026

MarketBeat Earnings Provider-linked mention 🇺🇸 United States

LGT Fund Management Co Ltd. Grows Stake in Johnson & Johnson $JNJ

LGT Fund Management Co Ltd. significantly increased its stake in Johnson & Johnson (NYSE:JNJ) by 770.7% in the first quarter, now owning 112,310 shares valued at $27.45 million. Other institutional investors have also adjusted their holdings, while Johnson & Johnson's stock is trading down …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +48.8%